Epoch Investment Partners Inc. Grows Stake in McKesson Corporation $MCK

Epoch Investment Partners Inc. boosted its stake in shares of McKesson Corporation (NYSE:MCK) by 56.1% during the 4th quarter, Holdings Channel.com reports. The firm owned 47,366 shares of the company’s stock after buying an additional 17,026 shares during the quarter. Epoch Investment Partners Inc.’s holdings in McKesson were worth $38,854,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Cullen Investment Group LTD. lifted its position in McKesson by 550.4% during the fourth quarter. Cullen Investment Group LTD. now owns 4,670 shares of the company’s stock valued at $3,811,000 after purchasing an additional 3,952 shares in the last quarter. Pensionfund Sabic purchased a new position in McKesson during the fourth quarter valued at $1,887,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its position in McKesson by 18.8% during the third quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 10,009 shares of the company’s stock valued at $7,732,000 after purchasing an additional 1,585 shares in the last quarter. PNC Financial Services Group Inc. lifted its position in McKesson by 24.3% during the third quarter. PNC Financial Services Group Inc. now owns 242,256 shares of the company’s stock valued at $187,152,000 after purchasing an additional 47,352 shares in the last quarter. Finally, Achmea Investment Management B.V. lifted its position in McKesson by 7.5% during the third quarter. Achmea Investment Management B.V. now owns 61,287 shares of the company’s stock valued at $47,347,000 after purchasing an additional 4,260 shares in the last quarter. 85.07% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at McKesson

In other news, CEO Brian S. Tyler sold 4,929 shares of McKesson stock in a transaction dated Tuesday, June 9th. The stock was sold at an average price of $763.00, for a total value of $3,760,827.00. Following the sale, the chief executive officer directly owned 22,845 shares of the company’s stock, valued at approximately $17,430,735. The trade was a 17.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Napoleon B. Rutledge, Jr. sold 133 shares of McKesson stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $764.00, for a total value of $101,612.00. Following the completion of the sale, the chief accounting officer directly owned 632 shares in the company, valued at $482,848. This trade represents a 17.39% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 11,822 shares of company stock valued at $8,986,212. 0.08% of the stock is owned by company insiders.

McKesson Stock Down 0.0%

Shares of McKesson stock opened at $783.88 on Monday. The stock’s 50-day simple moving average is $798.10 and its 200-day simple moving average is $846.19. McKesson Corporation has a 52 week low of $637.00 and a 52 week high of $999.00. The company has a market capitalization of $94.22 billion, a price-to-earnings ratio of 20.38, a PEG ratio of 1.29 and a beta of 0.31.

McKesson (NYSE:MCK) last announced its quarterly earnings data on Thursday, May 7th. The company reported $11.69 EPS for the quarter, beating the consensus estimate of $11.56 by $0.13. McKesson had a negative return on equity of 345.35% and a net margin of 1.18%.The business had revenue of $96.30 billion for the quarter, compared to the consensus estimate of $101.35 billion. During the same period in the previous year, the business earned $10.12 earnings per share. The business’s revenue was up 6.0% on a year-over-year basis. McKesson has set its FY 2027 guidance at 43.800-44.600 EPS. On average, equities analysts expect that McKesson Corporation will post 44.28 earnings per share for the current year.

McKesson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 1st. Stockholders of record on Monday, June 1st will be issued a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, June 1st. McKesson’s payout ratio is 8.53%.

Analyst Ratings Changes

Several equities analysts have recently commented on MCK shares. UBS Group boosted their price objective on McKesson from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Raymond James Financial set a $970.00 price objective on McKesson in a research report on Thursday, March 5th. Weiss Ratings downgraded McKesson from a “buy (b+)” rating to a “buy (b)” rating in a research report on Monday, May 18th. William Blair started coverage on McKesson in a research report on Tuesday, April 28th. They issued an “outperform” rating on the stock. Finally, Leerink Partners restated an “outperform” rating and issued a $1,085.00 price objective on shares of McKesson in a research report on Thursday, March 5th. Fourteen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, McKesson has an average rating of “Moderate Buy” and a consensus price target of $960.53.

About McKesson

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.